Modern oncology discovery depends on high-fidelity tumor-associated antigens like TROP-2 that preserve native ectodomain structure and deliver reliable, biologically relevant binding.
Conigen’s mammalian-expressed TROP-2 dimers maintain native-like quaternary conformation via a short, proprietary linker to stabilize the cis-dimer ectodomain for enhanced performance across antibody binding assays.
These bioactive TROP-2 dimers are produced in HEK293 cells and verified in ELISA, SPR, and BLI formats.
Importantly, our Fc-free dimers outperform monomers.
Available with flexible tags and custom formats, Conigen’s TROP-2 reagents empower your discovery from screening to characterization.
Start your next breakthrough with Conigen’s TROP-2.
